Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...
Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...
A novel combination of an investigational intravesical drug delivery system designed to provide sustained release of gemcitabine into the bladder (Gem-iDRS, Inlexzo) and systemic treatment with the ...
The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?
Explore new findings on bladder cancer and inflammation's role in immune suppression. Discover insights to improve treatment.
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.
Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the cancer more resistant to treatment, according to new research from ...
Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the cancer more resistant to treatment, according to new research from ...
The American Cancer Society estimates that over 80,000 individuals will be diagnosed with bladder cancer this year. Unfortunately, in the same year, it is estimated that over 15,000 deaths will be ...
About one quarter of patients with muscle-invasive bladder cancer (MIBC) may be treated and derive a benefit with the current standard chemotherapy. To better understand why some tumors resist ...
From a biomarker-driven strategy to delay or avoid cystectomy, to practice-changing perioperative immunotherapy, developments in bladder cancer frequently have made news over the past 12 months. The ...